Table 1
Patient, tumor, and treatment characteristics for 65 patients (70 tumors) receiving stereotactic ablative radiotherapy (SABR)
| Characteristic | Valuea |
|---|---|
| Age, year | 64 (22–95) |
| Men | 50 (77) |
| Primary cancer | |
| Lung | 49 (70) |
| Colorectal | 10 (14) |
| Other (breast, gastric, melanoma, germ cell, RCC) | 11 (16) |
| Treatment indication | |
| Primary lung (medically inoperable T1–T2) | 12 (17) |
| Relapse (primary lung and oligometastatic) | 24 (34) |
| Oligometastatic | 34 (49) |
| Previous radiation to chest | 20 (29) |
| Tumor location | |
| ≤ 1 cm from tracheobronchial tree | 24 (34) |
| > 1 cm but ≤ 2 cm from tracheobronchial tree | 12 (17) |
| Lesions intersecting mediastinum | 22 (31) |
| ≤ 1 cm from thoracic aorta | 12 (17) |
| Left laterality | 37 (53) |
| Lesion size (PTV), cc | 33.4 (7.3–461.5) |
| Total dose, Gy | 55 (30–60) |
| Dose per fraction, Gy | 9.75 (4–18) |
| Fractions | 5 (3–10) |
| BED10, Gy | 110 (48–151.2) |
| BED10 | |
| < 100 Gy | 16 (23) |
| ≥ 100 Gy | 54 (77) |
| BED3, Gy | 228 (90–378) |
| Treatment time, days | 10 (5–19) |
| Treatment time | |
| < 10 days | 30 (43) |
| ≥ 10 days | 40 (57) |
| Treatment on consecutive days | 6 (9) |
Table 2
Tumor and patient outcomes after stereotactic ablative radiotherapy (SABR) for central lung tumors
| Characteristic | Valuea |
|---|---|
| Response on 3-month PET/CT after SABR | |
| Complete response | 43 (61) |
| Partial response | 19 (27) |
| Progression | 2 (3) |
| Unknown (patient died before 3 months or imaging not performed) | 6 (9) |
| Locoregional control | |
| 2-year | 84% |
| 5-year | 70% |
| Median | Not reached |
| Overall survival | |
| 2-year | 52% |
| 5-year | 28% |
| Median | 28 months |
| 2-Year toxicity-free survival | 81% |
| All Toxicities (grade 2 or higher) | 17 (26.2%) |
| RT-induced pneumonitis | 9 (13.8%) |
| Brachial and recurrent laryngeal nerve injury | 3 (4.6%) |
| Esophagitis | 2 (3%) |
| Tracheal perforation | 1 (1.5%) |
| Fatal hemoptysis | 1 (1.5%) |
| Possible RT-related death | 1 (1.5%) |
| Toxicity, grade 5 (fatal) | 5 (7.7%) |
| RT-induced pneumonitis | 2 (3%) |
| Tracheal perforation | 1 (1.5%) |
| Fatal hemoptysis | 1 (1.5%) |
| Possible RT-related death | 1 (1.5%) |
Figure 1
Kaplan-Meier curves for locoregional relapse-free survival (LRFS). (A) LRFS of all patients according to primary tumor type (colorectal cancer vs. others). (B) LRFS of all patients according to radiographic response 3 months after radiotherapy (complete response vs. no complete response). Tick marks on lines indicate censored patients.
Figure 2
Kaplan-Meier curves for overall survival (OS). (A) OS of all patients according to development of a grade 3 or higher toxicity (vs. not). (B) OS of all patients according to primary tumor type (lung cancer vs. others). Tick marks on lines indicate censored patients.
Figure 3
Computed tomographic imaging examples of patients with a grade 3 or higher toxicity. (A) Patient with a tracheal rupture after reirradiation. (B) Patient with vocal cord paralysis after reirradiation (previous chest wall radiotherapy). The circled portion indicates the planning target volume.
Figure 4
Kaplan-Meier Curves for grade 3 or higher toxicity-free survival (TFS). (A) TFS for all patients according to reirradiation vs. no reirradiation. (B) TFS for all patients according to the distance of the planning target volume from the tracheobronchial tree (> 1 cm or ≤ 1 cm). Tick marks on lines indicate censored patients.